Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06087458
PHASE1/PHASE2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Sponsor: Perceive Biotherapeutics, Inc.

View on ClinicalTrials.gov

Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Official title: Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-06-21

Completion Date

2028-03

Last Updated

2025-10-15

Healthy Volunteers

No

Interventions

BIOLOGICAL

VOY-101

VOY-101

Locations (11)

Retina Macula Institute of AZ

Scottsdale, Arizona, United States

The Retina Partners

Encino, California, United States

Retinal Consultants Medical Group

Sacramento, California, United States

Retina Consultants San Diego

San Diego, California, United States

Star Retina

Burleson, Texas, United States

Retina Center of Texas

Southlake, Texas, United States

University of Utah John A. Moran Eye Center

Salt Lake City, Utah, United States

Sydney Retina Clinic and Day Surgery

Sydney, New South Wales, Australia

Cerulea Clinical Trials

East Melbourne, Victoria, Australia

Rambam Medical Center

Haifa, Israel

Tel-Aviv Sourasky Medical Center, Ophthalmology Division

Tel Aviv, Israel